CareDx, Inc (CDNA) key performance indicators and operating metrics (15 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Patient and Digital Solutions Revenue | 16M | FY2026-Q1 |
| Testing Services Revenue | 91M | FY2026-Q1 |
| Non-GAAP Net Income | 18M | FY2026-Q1 |
| Lab Products Revenue | 10M | FY2026-Q1 |
| Net Income Per Share (Non-GAAP, Diluted) | 0.34 USD_per_share | FY2026-Q1 |
| Testing Services Volume | 54.9K | FY2026-Q1 |
| Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization | 19M | FY2026-Q1 |
| Cash Flow from Operations | 4M | FY2026-Q1 |
| Product Revenue | 12.5M | FY2025-Q3 |
| Non-GAAP Gross Margin Percentage | 71.00 percent | FY2025-Q3 |
| Loss From Operations (GAAP) | -246K | FY2025-Q3 |
| Adjusted Testing Services Revenue | 65.9M | FY2025-Q2 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization Gain | 9.1M | FY2025-Q2 |
| Testing Volume | 47.5K | FY2025-Q2 |
Back to CDNA overview · CDNA earnings · CDNA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.